Steroid 21-hydroxylase (CYP21A2) Recombinant Protein | CYP21A2 recombinant protein

Recombinant Human Steroid 21-hydroxylase (CYP21A2)

Cat. Num. AAA957205

• Gene Names: CYP21A2; CAH1; CPS1; CA21H; CYP21; CYP21B; P450c21B
• Purity: Greater or equal to 85% purity as determined by SDS-PAGE.
• Synonyms: Steroid 21-hydroxylase (CYP21A2); Recombinant Human Steroid 21-hydroxylase (CYP21A2); 21-OHase; Cytochrome P-450c21; Cytochrome P450 21; Cytochrome P450 XXI; Cytochrome P450-C21; Cytochrome P450-C21B; CYP21A2 recombinant protein

• Host: E Coli or Yeast or Baculovirus or Mammalian Cell
• Purity/Purification: Greater or equal to 85% purity as determined by SDS-PAGE.
• Form/Format: Lyophilized or liquid (Format to be determined during the manufacturing process)
• Sequence Positions: 1-494a; Full Length
• Sequence: MLLLGLLLLPLLAGARLLWNWWKLRSLHLPPLAPGFLHLLQPDLPIYLLGLTQKFGPIYRLHLGLQDVVVLNSKRTIEEAMVKKWADFAGRPEPLTYKLVSKNYPDLSLGDYSLLWKAHKKLTRSALLLGIRDSMEPVVEQLTQEFCERMRAQPGTPVAIEEEFSLLTCSIICYLTFGDKIKDDNLMPAYYKCIQEVLKTWSHWSIQIVDVIPFLRFFPNPGLRRLKQAIEKRDHIVEMQLRQHKESLVAGQWRDMMDYMLQGVAQPSMEEGSGQLLEGHVHMAAVDLLIGGTETTANTLSWAVVFLLHHPEIQQRLQEELDHELGPGASSSRVPYKDRARLPLLNATIAEVLRLRPVVPLALPHRTTRPSSISGYDIPEGTVIIPNLQGAHLDETVWERPHEFWPDRFLEPGKNSRALAFGCGARVCLGEPLARLELFVVLTRLLQAFTLLPSGDALPSLQPLPHCSVILKMQPFQVRLQPRGMGAHSPGQNQ

• Production Note: Special Offer: The E Coli, Yeast host-expressed protein is manufactured from a stock plasmid containing the protein gene. E Coli, Yeasthost-expressed protein is stocked in different unit sizes ranging from as small as 10 ug to as large as 1 mg. Bulk inventory is also available. The E Coli, Yeast host-expressed protein has been ordered over and over again by researchers and has stood the test of time as both a robust protein and important target for the research community. It is part of our new program to make our most popular protein targets and corresponding hosts available in expanded unit sizes and with a quick processing time. Select E Coli, Yeast host-expressed protein for the fastest delivery among all hosts. Please contact our technical support team or email to [email protected] for more details.
• Preparation and Storage: Store at -20 degree C, for extended storage, conserve at -20 degree C or -80 degree C.

SDS-Page

Related Product Information for CYP21A2 recombinant protein

Specifically catalyzes the 21-hydroxylation of steroids. Required for the adrenal synthesis of mineralocorticoids and glucocorticoids.

Product Categories/Family for CYP21A2 recombinant protein

Cancer

References

Complete nucleotide sequence of two steroid 21-hydroxylase genes tandemly arranged in human chromosome a pseudogene and a genuine gene.Higashi Y., Yoshioka H., Yamane M., Gotoh O., Fujii-Kuriyama Y.Proc. Natl. Acad. Sci. U.S.A. 83:2841-2845(1986) Structure of human steroid 21-hydroxylase genes.White P.C., New M.I., Dupont B.Proc. Natl. Acad. Sci. U.S.A. 83:5111-5115(1986) Molecular characterization of the HLA-linked steroid 21-hydroxylase B gene from an individual with congenital adrenal hyperplasia.Rodrigues N.R., Dunham I., Yu C.Y., Carroll M.C., Porter R.R., Campbell R.D.EMBO J. 6:1653-1661(1987) Nonsense mutation causing steroid 21-hydroxylase deficiency.Globerman H., Amor M., Parker K.L., New M.I., White P.C.J. Clin. Invest. 82:139-144(1988) R339H and P453S CYP21 mutations associated with nonclassic steroid 21-hydroxylase deficiency that are not apparent gene conversions.Helmberg A., Tusie-Luna M.-T., Tabarelli M., Kofler R., White P.C.Mol. Endocrinol. 6:1318-1322(1992) Linkage analysis of the C4A/C4B copy number variation and polymorphisms of the adjacent steroid 21-hydroxylase gene in a healthy population.Blasko B., Banlaki Z., Gyapay G., Pozsonyi E., Sasvari-Szekely M., Rajczy K., Fust G., Szilagyi A.Mol. Immunol. 46:2623-2629(2009) Complete sequencing and characterization of 21,243 full-length human cDNAs.Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.Nat. Genet. 36:40-45(2004) The DNA sequence and analysis of human chromosome 6.Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L., Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R., Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D., Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H., Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J., Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V., Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J., Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E., Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J., French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J., Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C., Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A., Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R., Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M., Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A., Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L., Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I., Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y., Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E., Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A., Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W., Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J., Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M., Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I., Rogers J., Beck S.Nature 425:805-811(2003) Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W., Venter J.C. A de novo pathological point mutation at the 21-hydroxylase locus implications for gene conversion in the human genome.Collier S., Tassabehji M., Sinnott P., Strachan T.Nat. Genet. 3:260-265(1993) Mapping of steroid 21-hydroxylase genes adjacent to complement component C4 genes in HLA, the major histocompatibility complex in man.Carroll M.C., Campbell R.D., Porter R.R.Proc. Natl. Acad. Sci. U.S.A. 82:521-525(1985) Mutation in the CYP21B gene (Ile-172-->Asn) causes steroid 21-hydroxylase deficiency.Amor M., Parker K.L., Globerman H., New M.I., White P.C.Proc. Natl. Acad. Sci. U.S.A. 85:1600-1604(1988) P450XXI (steroid 21-hydroxylase) gene deletions are not found in family studies of congenital adrenal hyperplasia.Matteson K.J., Phillips J.A. III, Miller W.L., Chung B.C., Orlando P.J., Frisch H., Ferrandez A., Burr I.M.Proc. Natl. Acad. Sci. U.S.A. 84:5858-5862(1987) Mutations of P450c21 (steroid 21-hydroxylase) at Cys428, Val281, and Ser268 result in complete, partial, or no loss of enzymatic activity, respectively.Wu D.-A., Chung B.-C.J. Clin. Invest. 88:519-523(1991) Molecular genetics of 21-hydroxylase deficient late-onset adrenal hyperplasia.Gunn S.K., Sherman L.D., Therrell B.L., Owerbach D.I.Semin. Reprod. Endocrinol. 11:347-352(1993) Mutations in steroid 21-hydroxylase (CYP21) .White P.C., Tusie-Luna M.-T., New M.I., Speiser P.W.Hum. Mutat. 3:373-378(1994) Molecular genetic analysis of nonclassic steroid 21-hydroxylase deficiency associated with HLA-B14,DR1.Speiser P.W., New M.I., White P.C.N. Engl. J. Med. 319:19-23(1988) A missense mutation at Ile172-->Asn or Arg356-->Trp causes steroid 21-hydroxylase deficiency.Chiou S.-H., Hu M.-C., Chung B.-C.J. Biol. Chem. 265:3549-3552(1990) Substitution of Ile-172 to Asn in the steroid 21-hydroxylase B (P450c21B) gene in a Finnish patient with the simple virilizing form of congenital adrenal hyperplasia.Partanen J., Campbell R.D.Hum. Genet. 87:716-720(1991) A mutation (Pro-30 to Leu) in CYP21 represents a potential nonclassic steroid 21-hydroxylase deficiency allele.Tusie-Luna M.T., Speiser P.W., Dumic M., New M.I., White P.C.Mol. Endocrinol. 5:685-692(1991) Disease expression and molecular genotype in congenital adrenal hyperplasia due to 21-hydroxylase deficiency.Speiser P.W., Dupont J., Zhu D., Serrat J., Buegeleisen M., Tusie-Luna M.-T., Lesser M., New M.I., White P.C.J. Clin. Invest. 90:584-595(1992) Pro-453 to Ser mutation in CYP21 is associated with nonclassic steroid 21-hydroxylase deficiency.Owerbach D., Sherman L., Ballard A.L., Azziz R.Mol. Endocrinol. 6:1211-1215(1992) Steroid 21-hydroxylase deficiency three additional mutated alleles and establishment of phenotype-genotype relationships of common mutations.Wedell A., Ritzen E.M., Haglund-Stengler B., Luthman H.Proc. Natl. Acad. Sci. U.S.A. 89:7232-7236(1992) Steroid 21-hydroxylase (P450c21) a new allele and spread of mutations through the pseudogene.Wedell A., Luthman H.Hum. Genet. 91:236-240(1993) Screening of CYP21 gene mutations in 129 French patients affected by steroid 21-hydroxylase deficiency.Barbat B., Bogyo A., Raux-Demay M.-C., Kuttenn F., Boue J., Simon-Bouy B., Serre J.-L., Boue A., Mornet E.Hum. Mutat. 5:126-130(1995) E380D a novel point mutation of CYP21 in an HLA-homozygous patient with salt-losing congenital adrenal hyperplasia due to 21-hydroxylase deficiency.Kirby-Keyser L., Porter C.C., Donohoue P.A.3.0.CO;2-Z>Hum. Mutat. 9:181-182(1997) A cluster of missense mutations at Arg356 of human steroid 21-hydroxylase may impair redox partner interaction.Lajic S., Levo A., Nikoshkov A., Lundberg Y., Partanen J., Wedell A.Hum. Genet. 99:704-709(1997) Synergistic effect of partially inactivating mutations in steroid 21-hydroxylase deficiency.Nikoshkov A., Lajic S., Holst M., Wedell A., Luthman H.J. Clin. Endocrinol. Metab. 82:194-199(1997) Molecular genetic analysis of patients carrying steroid 21-hydroxylase deficiency in the Mexican population identification of possible new mutations and high prevalence of apparent germ-line mutations.Ordonez-Sanchez M.L., Ramirez-Jimenez S., Lopez-Gutierrez A.U., Riba L., Gamboa-Cardiel S., Cerrillo-Hinojosa M., Altamirano-Bustamante N., Calzada-Leon R., Robles-Valdes C., Mendoza-Morfin F., Tusie-Luna M.T.Hum. Genet. 102:170-177(1998) Naturally occurring mutants of human steroid 21-hydroxylase (P450c21) pinpoint residues important for enzyme activity and stability.Nikoshkov A., Lajic S., Vlamis-Gardikas A., Tranebjaerg L., Holst M., Wedell A., Luthman H.J. Biol. Chem. 273:6163-6165(1998) Effects of missense mutations and deletions on membrane anchoring and enzyme function of human steroid 21-hydroxylase (P450c21) .Lajic S., Nikoshkov A., Holst M., Wedell A.Biochem. Biophys. Res. Commun. 257:384-390(1999) Mutation analysis in patients with congenital adrenal hyperplasia in the Spanish population identification of putative novel steroid 21-hydroxylase deficiency alleles associated with the classic form of the disease.Lobato M.N., Ordonez-Sanchez M.L., Tusie-Luna M.T., Meseguer A.Hum. Hered. 49:169-175(1999) Identification of CYP21 mutations, one novel, by single strand conformational polymorphism (SSCP) analysis.Witchel S.F., Smith R., Suda-Hartman M.3.3.CO;2-E>Hum. Mutat. 13:172-172(1999) Steroid 21-hydroxylase deficiency mutational spectrum in Denmark, three novel mutations, and in vitro expression analysis.Ohlsson G., Mueller J., Skakkebaek N.E., Schwartz M.3.0.CO;2-0>Hum. Mutat. 13:482-486(1999) A rapid screening for steroid 21-hydroxylase mutations in patients with congenital adrenal hyperplasia.Kapelari K., Ghanaati Z., Wollmann H., Ventz M., Ranke M.B., Kofler R., Peters H.3.0.CO;2-0>Hum. Mutat. 13:505-505(1999) A novel missense mutation, GLY424SER, in Brazilian patients with 21-hydroxylase deficiency.Billerbeck A.E.C., Bachega T.A.S.S., Frazatto E.T., Nishi M.Y., Goldberg A.C., Marin M.L.C., Madureira G., Monte O., Arnhold I.J.P., Mendonca B.B.J. Clin. Endocrinol. Metab. 84:2870-2872(1999) Molecular analysis of Japanese patients with steroid 21-hydroxylase deficiency.Asanuma A., Ohura T., Ogawa E., Sato S., Igarashi Y., Matsubara Y., Iinuma K.J. Hum. Genet. 44:312-317(1999) Mutation screening in British 21-hydroxylase deficiency families and development of novel microsatellite based approaches to prenatal diagnosis.Lako M., Ramsden S., Campbell R.D., Strachan T.J. Med. Genet. 36:119-124(1999) Characterization of single-nucleotide polymorphisms in coding regions of human genes.Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N., Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L., Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q., Lander E.S.Nat. Genet. 22:231-238(1999) ErratumCargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N., Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L., Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q., Lander E.S.Nat. Genet. 23:373-373(1999) Predicting phenotype in steroid 21-hydroxylase deficiency? Comprehensive genotyping in 155 unrelated, well defined patients from southern Germany.Krone N., Braun A., Roscher A.A., Knorr D., Schwarz H.P.J. Clin. Endocrinol. Metab. 85:1059-1065(2000) Molecular analysis of CYP-21 mutations for congenital adrenal hyperplasia in Singapore.Loke K.Y., Lee Y.S., Lee W.W.R., Poh L.K.S.Horm. Res. 55:179-184(2001) Phenotype-genotype correlation in 56 women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency.Deneux C., Tardy V., Dib A., Mornet E., Billaud L., Charron D., Morel Y., Kuttenn F.J. Clin. Endocrinol. Metab. 86:207-213(2001) Mutational spectrum of the steroid 21-hydroxylase gene in Austria identification of a novel missense mutation.Baumgartner-Parzer S.M., Schulze E., Waldhaeusl W., Pauschenwein S., Rondot S., Nowotny P., Meyer K., Frisch H., Waldhauser F., Vierhapper H.J. Clin. Endocrinol. Metab. 86:4771-4775(2001) Novel mutations in the human CYP21 gene.Levo A., Partanen J.Prenat. Diagn. 21:885-889(2001) Non-classical 21-hydroxylase deficiency in children association of adrenocorticotropic hormone-stimulated 17-hydroxyprogesterone with the risk of compound heterozygosity with severe mutations.Ezquieta B., Cueva E., Varela J., Oliver A., Fernandez J., Jariego C.Acta Paediatr. 91:892-898(2002) Novel mutations in CYP21 detected in individuals with hyperandrogenism.Lajic S., Clauin S., Robins T., Vexiau P., Blanche H., Bellanne-Chantelot C., Wedell A.J. Clin. Endocrinol. Metab. 87:2824-2829(2002) Three novel mutations in CYP21 gene in Brazilian patients with the classical form of 21-hydroxylase deficiency due to a founder effect.Billerbeck A.E.C., Mendonca B.B., Pinto E.M., Madureira G., Arnhold I.J.P., Bachega T.A.S.S.J. Clin. Endocrinol. Metab. 87:4314-4317(2002) Mutational spectrum of congenital adrenal hyperplasia in Slovenian patients a novel Ala15Thr mutation and Pro30Leu within a larger gene conversion associated with a severe form of the disease.Dolzan V., Stopar-Obreza M., Zerjav-Tansek M., Breskvar K., Krzisnik C., Battelino T.Eur. J. Endocrinol. 149:137-144(2003) Follow-up of 68 children with congenital adrenal hyperplasia due to 21-hydroxylase deficiency relevance of genotype for management.Pinto G., Tardy V., Trivin C., Thalassinos C., Lortat-Jacob S., Nihoul-Fekete C., Morel Y., Brauner R.J. Clin. Endocrinol. Metab. 88:2624-2633(2003) CYP21 gene mutation analysis in 198 patients with 21-hydroxylase deficiency in The Netherlands six novel mutations and a specific cluster of four mutations.Stikkelbroeck N.M., Hoefsloot L.H., de Wijs I.J., Otten B.J., Hermus A.R., Sistermans E.A.J. Clin. Endocrinol. Metab. 88:3852-3859(2003) Molecular genetic analysis of Tunisian patients with a classic form of 21-hydroxylase deficiency identification of four novel mutations and high prevalence of Q318X mutation.Kharrat M., Tardy V., M'Rad R., Maazoul F., Jemaa L.B., Refai M., Morel Y., Chaabouni H.J. Clin. Endocrinol. Metab. 89:368-374(2004) Three novel mutations in Japanese patients with 21-hydroxylase deficiency.Usui T., Nishisho K., Kaji M., Ikuno N., Yorifuji T., Yasuda T., Kuzuya H., Shimatsu A.Horm. Res. 61:126-132(2004) Functional analysis of two recurrent amino acid substitutions in the CYP21 gene from Italian patients with congenital adrenal hyperplasia.Barbaro M., Lajic S., Baldazzi L., Balsamo A., Pirazzoli P., Cicognani A., Wedell A., Cacciari E.J. Clin. Endocrinol. Metab. 89:2402-2407(2004) Detection and assignment of CYP21 mutations using peptide mass signature genotyping.Zeng X., Witchel S.F., Dobrowolski S.F., Moulder P.V., Jarvik J.W., Telmer C.A.Mol. Genet. Metab. 82:38-47(2004) 21-Hydroxylase and 11beta-hydroxylase mutations in Romanian patients with classic congenital adrenal hyperplasia.Grigorescu Sido A., Weber M.M., Grigorescu Sido P., Clausmeyer S., Heinrich U., Schulze E.J. Clin. Endocrinol. Metab. 90:5769-5773(2005) p.H62L, a rare mutation of the CYP21 gene identified in two forms of 21-hydroxylase deficiency.Menassa R., Tardy V., Despert F., Bouvattier-Morel C., Brossier J.P., Cartigny M., Morel Y.J. Clin. Endocrinol. Metab. 93:1901-1908(2008) Inhibition of CYP21A2 enzyme activity caused by novel missense mutations identified in Brazilian and Scandinavian patients.Soardi F.C., Barbaro M., Lau I.F., Lemos-Marini S.H., Baptista M.T., Guerra-Junior G., Wedell A., Lajic S., de Mello M.P.J. Clin. Endocrinol. Metab. 93:2416-2420(2008) Functional and structural consequences of a novel point mutation in the CYP21A2 gene causing congenital adrenal hyperplasia potential relevance of helix C for P450 oxidoreductase-21-hydroxylase interaction.Riepe F.G., Hiort O., Grotzinger J., Sippell W.G., Krone N., Holterhus P.M.J. Clin. Endocrinol. Metab. 93:2891-2895(2008) Phenotype-genotype correlations of 13 rare CYP21A2 mutations detected in 46 patients affected with 21-hydroxylase deficiency and in one carrier.Tardy V., Menassa R., Sulmont V., Lienhardt-Roussie A., Lecointre C., Brauner R., David M., Morel Y.J. Clin. Endocrinol. Metab. 95:1288-1300(2010) +Additional computationally mapped references.<p>Provides general information on the entry.

NCBI and Uniprot Product Information

• NCBI GI #: 323510663
• NCBI GeneID: 1589
• NCBI Accession #: NP_000491.4
• NCBI GenBank Nucleotide #: NM_000500.7
• UniProt Accession #: P08686; P04033; Q01204; Q08AG8; Q16749; Q16806; Q5ST44; Q96NU8; A2BHY6
• Molecular Weight: 57.9 kDa
• NCBI Official Full Name: steroid 21-hydroxylase isoform a
• NCBI Official Synonym Full Names: cytochrome P450 family 21 subfamily A member 2
• NCBI Official Symbol: CYP21A2
• NCBI Official Synonym Symbols: CAH1; CPS1; CA21H; CYP21; CYP21B; P450c21B
• NCBI Protein Information: steroid 21-hydroxylase
• UniProt Protein Name: Steroid 21-hydroxylase
• UniProt Gene Name: CYP21A2
• UniProt Synonym Gene Names: CYP21; CYP21B
• UniProt Entry Name: CP21A_HUMAN

NCBI Description

This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and hydroxylates steroids at the 21 position. Its activity is required for the synthesis of steroid hormones including cortisol and aldosterone. Mutations in this gene cause congenital adrenal hyperplasia. A related pseudogene is located near this gene; gene conversion events involving the functional gene and the pseudogene are thought to account for many cases of steroid 21-hydroxylase deficiency. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]

Uniprot Description

CYP21A2: Specifically catalyzes the 21-hydroxylation of steroids. Required for the adrenal synthesis of mineralocorticoids and glucocorticoids. Defects in CYP21A2 are the cause of adrenal hyperplasia type 3 (AH3). AH3 is a form of congenital adrenal hyperplasia, a common recessive disease due to defective synthesis of cortisol. Congenital adrenal hyperplasia is characterized by androgen excess leading to ambiguous genitalia in affected females, rapid somatic growth during childhood in both sexes with premature closure of the epiphyses and short adult stature. Four clinical types: 'salt wasting' (SW, the most severe type), 'simple virilizing' (SV, less severely affected patients), with normal aldosterone biosynthesis, 'non-classic form' or late onset (NC or LOAH), and 'cryptic' (asymptomatic). Belongs to the cytochrome P450 family.

Protein type: EC 1.14.99.10; Oxidoreductase; Lipid Metabolism - C21-steroid hormone

Chromosomal Location of Human Ortholog: 6p21.3

Cellular Component: endoplasmic reticulum membrane

Molecular Function: heme binding; iron ion binding; oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen; steroid binding; steroid hydroxylase activity

Biological Process: glucocorticoid biosynthetic process; mineralocorticoid biosynthetic process; steroid metabolic process; sterol metabolic process; xenobiotic metabolic process

Disease: Adrenal Hyperplasia, Congenital, Due To 21-hydroxylase Deficiency